NATCO Pharma, Lupin get USFDA approval for cancer drug

3 Jun 2026via Business StandardSource

English हिंदी తెలుగు தமிழ்ಕನ್ನಡ मराठी বাংলা ગુજરાતી

NATCO Pharma, Lupin get USFDA approval for Eribulin Mesylate injection. This greenlight allows both firms to launch a generic version of the cancer drug in the US market. The approval is expected to drive near-term revenue via market exclusivity. 📊 STOCKS: NATCOPHARM, LUPIN | 🏢 SECTOR: Pharma | #MEDIUMIMPACT #USFDA

#USFDA#approval#generic#cancer-drug

Stocks mentioned

LUPINLUPIN LIMITED

⚠️ This brief is AI-generated from public news sources for informational purposes only. Not investment advice. Always consult a SEBI-registered advisor before trading.

gold and silver prices remain rangebound →

Trade smarter on NSE

Live option chains, FII flows, PCR, AI analysis — for NIFTY, BANKNIFTY & 200+ F&O stocks.

Start for ₹1 →